Skip to content

US · KTTA · BIOTECHNOLOGY

Pasithea Therapeutics Corp. (KTTA) intrinsic value and stock valuation

$0.48as of 2026-11-21 · Mkt cap 3.35M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pasithea Therapeutics Corp. DCF and intrinsic value

InvestorsCraft values KTTA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KTTA’s statements →

Pasithea Therapeutics Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Miami Beach, FL 33139 pasithea.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-20.43M
20202025
Free cash flow
-$-15.21B
20202025
Total equity
$55.2M+196.7% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$20K
Operating income-$-20.86M-$-14.25M-$-15.98M-$-12.59M-$-4.51M
Net income-$-20.43M-$-13.9M-$-15.96M-$-13.94M-$-2.17M
EPSd-$-2.91M-$-12.64M-$-12.98M-$-11.06M-$-1.89M
Operating cash flow-$-15.21B-$-13.92M-$-13.43M-$-13.69M-$-3.17M
Capital expenditure$0.00-$0.00-$-30K-$-110K-$-20K
Free cash flow-$-15.21B-$-13.92M-$-13.46M-$-13.8M-$-3.2M
Total assets$60.2M$16.1M$26.1M$45.2M$53.3M
Total debt$0.00$0.00$80K$500K$0.00
Net debt-$-55.16M-$-6.92M-$-16.25M-$-32.58M-$-52.97M
Total equity$55.2M$14.8M$23.4M$42.5M$51.4M
Cash and short-term investments$55.2M$6.92M$16.3M$33.1M$53M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$20K
Cost of revenue$0.00$0.00$0.00$10K$20K
Gross profit$0.00$0.00$0.00-$-10K-$0.00
Research and development expenses$7.98M$7.2M$8.1M$2.67M$0.00
Selling, general and administrative expenses$12.9M$7.05M$7.88M$9.92M$4.51M
Other expenses$0.00$0.00$7.88M$0.00$4.51M
Operating expenses$20.9M$14.3M$16M$12.6M$4.51M
Cost and expenses$20.9M$14.3M$16M$12.6M$4.52M
Interest income$330K$420K$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$660K$650K$650K$10K$0.00
Ebitda-$-20.19M-$-13.6M-$-15.33M-$-11.72M-$-4.51M
Operating income-$-20.86M-$-14.25M-$-15.98M-$-12.59M-$-4.51M
Total other income/expenses, net$430K$350K$470K$860K$2.33M
Income before tax-$-20.43M-$-13.9M-$-15.51M-$-11.73M-$-2.17M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-20.43M-$-13.9M-$-15.96M-$-13.94M-$-2.17M
Weighted average shares outstanding$7.03M$1.1M$1.26M$1.26M$1.15M
Weighted average diluted shares outstanding$7.03M$1.1M$1.23M$1.26M$1.15M
Balance sheet
20252024202320222021
Cash and short-term investments$55.2M$6.92M$16.3M$33.1M$53M
Net receivables$0.00$0.00$40K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$56.5M$7.37M$16.7M$34.1M$53.3M
Property, plant and equipment, net$0.00$120K$220K$630K$20K
Goodwill and intangible assets$3.78M$8.57M$9.2M$9.83M$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.78M$8.7M$9.42M$11.1M$20K
Total assets$60.2M$16.1M$26.1M$45.2M$53.3M
Accounts payable$0.00$1.12M$0.00$1.48M$0.00
Short-term debt$0.00$0.00$80K$160K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.97M$1.12M$2.63M$1.88M$450K
Long-term debt$0.00$0.00$0.00$340K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$50K$160K$80K$800K$1.45M
Capital lease obligations$0.00$0.00$80K$500K$0.00
Total liabilities$5.02M$1.28M$2.72M$2.68M$1.9M
Common stock$0.00$0.00$0.00$0.00$20K
Retained earnings-$-70.01M-$-49.58M-$-35.32M-$-19.36M-$-2.21M
Accumulated other comprehensive income (loss)$20K-$-10K-$0.00-$0.00-$-10K
Total equity$55.2M$14.8M$23.4M$42.5M$51.4M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$80K$500K$0.00
Net debt-$-55.16M-$-6.92M-$-16.25M-$-32.58M-$-52.97M
Cash flow statement
20252024202320222021
Net income-$-20.43B-$-13.9M-$-15.51M-$-11.73M-$-2.17M
Depreciation and amortization$32.4M$650K$650K$10K$0.00
Stock-based compensation$297.5M$770K$590K$840K$470K
Change in working capital-$-320K-$-1.52M$1.57M$850K$110K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$440K
Net cash provided by operating activities-$-15.21B-$-13.92M-$-13.43M-$-13.69M-$-3.17M
Investments in property, plant and equipment$0.00$0.00-$-30K-$-110K-$-20K
Acquisitions, net$0.00$0.00$0.00-$-2.19M$0.00
Net cash used for investing activities$11M$0.00$400K-$-2.93M-$-20K
Common stock issued$64M$4.52M$0.00$0.00$50.2M
Common stock repurchased$0.00$0.00-$-3.73M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$63.5B$4.52M-$-3.73M-$-3.21M$55.9M
Net change in cash$48.3B-$-9.41M-$-16.76M-$-19.88M$52.7M
Cash at end of period$55.3B$6.92M$16.3M$33.1M$53M
Operating cash flow-$-15.21B-$-13.92M-$-13.43M-$-13.69M-$-3.17M
Capital expenditure$0.00-$0.00-$-30K-$-110K-$-20K
Free cash flow-$-15.21B-$-13.92M-$-13.46M-$-13.8M-$-3.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pasithea Therapeutics Corp.

        Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.

        CEO
        Tiago Reis Marques
        Employees
        5
        Beta
        0.29

        Explore

        Frequently asked questions

        What is the intrinsic value of Pasithea Therapeutics Corp. (KTTA)?

        InvestorsCraft does not currently publish an intrinsic value for KTTA. How the IC value is calculated.

        Is KTTA undervalued?

        InvestorsCraft does not publish an undervaluation signal for KTTA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.